Literature DB >> 22213098

Identification of a functional variant in SPLUNC1 associated with nasopharyngeal carcinoma susceptibility among Malaysian Chinese.

Poh-Yin Yew1, Taisei Mushiroda, Kazuma Kiyotani, Gopala Krishnan Govindasamy, Lee-Fah Yap, Soo-Hwang Teo, Paul Vey-Hong Lim, Selvaratnam Govindaraju, Kananathan Ratnavelu, Choon-Kook Sam, Yoke-Yeow Yap, Alan Soo-Beng Khoo, Kin-Choo Pua, Yusuke Nakamura, Ching-Ching Ng.   

Abstract

Nasopharyngeal carcinoma (NPC) is a multifactorial and polygenic disease with high incidence in Asian countries. Epstein-Barr virus infection, environmental and genetic factors are believed to be involved in the tumorigenesis of NPC. The association of single nucleotide polymorphisms (SNPs) in LPLUNC1 and SPLUNC1 genes with NPC was investigated by performing a two-stage case control association study in a Malaysian Chinese population. The initial screening consisted of 81 NPC patients and 147 healthy controls while the replication study consisted of 366 NPC patients and 340 healthy controls. The combined analysis showed that a SNP (rs2752903) of SPLUNC1 was significantly associated with the risk of NPC (combined P = 0.00032, odds ratio = 1.62, 95% confidence interval = 1.25-2.11). In the subsequent dense fine mapping of SPLUNC1 locus, 36 SNPs in strong linkage disequilibrium with rs2752903 (r(2) ≥ 0.85) were associated with NPC susceptibility. Screening of these variants by electrophoretic mobility shift and luciferase reporter assays showed that rs1407019 located in intron 3 (r(2)  = 0.994 with rs2752903) caused allelic difference in the binding of specificity protein 1 (Sp1) transcription factor and affected luciferase activity. This SNP may consequently alter the expression of SPLUNC1 in the epithelial cells. In summary, our study suggested that rs1407019 in intronic enhancer of SPLUNC1 is associated with NPC susceptibility in which its A allele confers an increased risk of NPC in the Malaysian Chinese population.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22213098     DOI: 10.1002/mc.21857

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  7 in total

Review 1.  Transcriptional regulation and its misregulation in disease.

Authors:  Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-03-14       Impact factor: 41.582

2.  Ovocalyxin-36 is a pattern recognition protein in chicken eggshell membranes.

Authors:  Cristianne M M Cordeiro; Hamed Esmaili; George Ansah; Maxwell T Hincke
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

3.  Identification of novel SNPs in differentially expressed genes and its association with horn cancer of Bos indicus bullocks by next-generation sequencing.

Authors:  P G Koringa; S J Jakhesara; D N Rank; C G Joshi
Journal:  3 Biotech       Date:  2016-01-27       Impact factor: 2.406

4.  Identification of BPIFA1/SPLUNC1 as an epithelium-derived smooth muscle relaxing factor.

Authors:  Tongde Wu; Julianne Huang; Patrick J Moore; Michael S Little; William G Walton; Robert C Fellner; Neil E Alexis; Y Peter Di; Matthew R Redinbo; Stephen L Tilley; Robert Tarran
Journal:  Nat Commun       Date:  2017-02-06       Impact factor: 14.919

5.  A clinical study on the factors associated with nasopharyngeal carcinoma among the Chinese population.

Authors:  Zhenfang Gu; Dongyu Hu; Wei Cui; Haiying Liu; Chunmei Zhang
Journal:  Exp Ther Med       Date:  2021-02-19       Impact factor: 2.447

6.  Effect of miR-25 on Proliferation of Nasopharyngeal Carcinoma Cells through Wnt/β-Catenin Signaling Pathway.

Authors:  Haixia He; Kun Yuan; Wei Chen
Journal:  Biomed Res Int       Date:  2021-08-26       Impact factor: 3.411

7.  Detection of nasopharyngeal carcinoma susceptibility with single nucleotide polymorphism analysis using next-generation sequencing technology.

Authors:  Mu-Yun Wu; Shu-Jing Huang; Fan Yang; Xin-Tian Qin; Dong Liu; Ying Ding; Shu Yang; Xi-Cheng Wang
Journal:  Oncotarget       Date:  2017-04-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.